Sierra Oncology (SRRA) Stock Analysis

What Sierra Oncology does

Sierra Oncology, Inc. is a biopharmaceutical firm focused on the late-stage research, development, and commercialization of therapeutic solutions for patients with blood disorders and various cancers. The company's primary drug candidate is momelotinib, an orally administered, selective inhibitor that targets Janus kinase 1 (JAK1), JAK2, and Activin A receptor type 1 (ACVR1). Additionally, its pipeline includes SRA515, a selective bromodomain-containing protein 4 inhibitor, and SRA737, an orally bioavailable small molecule designed to inhibit Checkpoint kinase 1. Sierra Oncology maintains license agreements with partners such as Carna Biosciences, Inc. for the development and commercialization of SRA141 (a small molecule kinase inhibitor targeting Cdc7), along with AstraZeneca AB and CRT Pioneer Fund LP. Established in 2003, the company was initially known as ProNAi Therapeutics, Inc. before rebranding to Sierra Oncology, Inc. in January 2017. Headquartered in San Mateo, California, Sierra Oncology, Inc. has been operating as a subsidiary of GSK plc since July 1, 2022.

Key metrics

ETFs linked to SRRA

Broad-market and Healthcare sector ETFs an investor holding Sierra Oncology is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how SRRA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Sierra Oncology?

Sierra Oncology trades under the ticker SRRA on NASDAQ.

Which exchange is SRRA listed on?

SRRA is listed on NASDAQ.

What sector does Sierra Oncology operate in?

Sierra Oncology is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze SRRA in a portfolio?

PortView shows SRRA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.